QR Code Drug Traceability | UPSC GS-2 | UPSCPDF
UPSCPDF Editorial Analysis: India
Key Takeaways | Quick Facts Box | How India Got Here — A Traceability Timeline | Two Things Students Confuse | Constitutional & Legal Foundations | The Drug-Safety & Traceability Architecture | The International Frame | Marks Breakdown | More Mains Angles (Multi-GS) | Additional Essay Angles | Key Actors & Stakeholders | Quick Revision Tags | 📚 Explore More UPSC Editorial Analyses | 🇮🇳 UPSCPDF Editorial Analysis
From a curated list of top brands to entire therapeutic classes — how India's expanded Schedule H2 track-and-trace framework aims to fight counterfeit and substandard medicines, blunt antimicrobial resistance, and rebuild trust in Indian pharma. The promise is real; the test is implementation. The Ministry of Health & Family Welfare (MoHFW) has notified the Drugs (Seventh Amendment) Rules, 2026 (via gazette notification G.S.R. 506(E) dated 22 June 2026), expanding the QR code-based "track-and-trace" framework under Schedule H2 of the Drugs Rules, 1945. Earlier confined to the country's top 300 pharmaceutical brands, the requirement now covers four entire high-risk therapeutic classes — all vaccines, all antimicrobials, all narcotic and psychotropic drugs (covered under the NDPS Act, 1985), and all anti-cancer medicines. Manufacturers must print or affix a barcode/QR code carrying nine key data elements on the primary (or, where space is short, secondary) packaging, enabling aut
⏱ Reading time: ~34 min
